【医保药品丙类目录进度不及预期 商保目录征求意见启动】金十数据4月10日讯，两份旨在纾解创新药品支付困难的药品目录在今年牵动着药企和保司的目光，近期呈现出不同的动向。由国家医保局操刀的药品丙类目录原定于4月1日开始申报，目前未有落地动作；另一份中国保险协会牵头的商保目录公布了30种A类药品的目录清单，多为高值肿瘤药物。有创新药企人士分析，相较国谈药物经济学和基金安全测算两把尺子，丙类目录的遴选主要依靠药物经济学评价，初版目录数量预计不会很多，约10—20种。行业普遍预测，丙类目录或为因价格高昂失去医保资格的CAR-T、ADC等产品打开口子，已有多款药品和适应证进入医保的PD-1很可能不在制定预期中。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.